Keywords: Merck & Co, Lycea, Autoimmune diseases, Licensing

Merck & Co links up with Lycera in $300 million deal for autoimmune disease drugs

Article | 04 March 2011

Print This

Pharma giant Merck & Co (NYSE: MRK) has signed a deal with fellow USA-based drug start-up Lycera Corp to discover, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in